JAC Advance Access originally published online on April 8, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 882-884
© 2004 The British Society for Antimicrobial Chemotherapy
Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea
Department of Microbiology, Leeds Teaching Hospitals and University of Leeds, Old Medical School, Leeds LS1 3EX, UK
Received 4 December 2003; returned 2 February 2004; revised and accepted 10 February 2004
Objectives: Clostridium difficile diarrhoea (CDD) cases treated with intravenous immunoglobulin during a 2 year period were reviewed to determine disease severity and response to treatment.
Patients and methods: Of 580 CD cytotoxin-positive patients, five received intravenous immunoglobulin because of protracted and/or recurrent CDD (median duration 50 days, range 45–64); two had biopsy- proven pseudomembranous colitis. The five patients received a median three non-CDD antibiotic courses (range 2–8). Indices of CDD severity included hypoalbuminaemia (n = 5, median 27 g/L, range 11–29), marked hypokalaemia (n = 3, range 1.9–2.7 mM), markedly raised peripheral white cell count (n = 3, 18–34 x 109 cells/L), abdominal signs (n = 3) and pyrexia (n = 1). The five cases received metronidazole for median 17 days (range 0–63) plus vancomycin for median 14 days (range 10–42) before intravenous immunoglobulin. One also received rifampicin plus vancomycin and one was given Saccharomyces boulardii.
Results: Intravenous immunoglobulin was given at a dosage of 300–500 mg/kg (most commonly 400 mg/kg) for one dose (two patients), two doses (two patients) and in one case for six doses. The latter patient died of intractable CDD, three had a good therapeutic response to intravenous immunoglobulin and CDD recurred within 6 weeks in one case. In the three successfully treated cases, CDD resolved within 11 days.
Conclusions: Intravenous immunoglobulin is useful for the treatment of intractable and severe CDD. Controlled studies are needed to assess the true value of this and other forms of passive immunotherapy.
Keywords: pseudomembranous colitis, antibiotics, immunotherapy
* Tel: +44-113-392-6818; Fax. +44-113-343-5649; E-mail: Mark.Wilcox{at}leedsth.nhs.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. P. Kelly A 76-Year-Old Man With Recurrent Clostridium difficile-Associated Diarrhea: Review of C difficile Infection JAMA, March 4, 2009; 301(9): 954 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Monaghan, T Boswell, and Y R Mahida Recent advances in Clostridium difficile-associated disease Postgrad. Med. J., March 1, 2009; 85(1001): 152 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Kelly and J. T. LaMont Clostridium difficile -- More Difficult Than Ever N. Engl. J. Med., October 30, 2008; 359(18): 1932 - 1940. [Full Text] [PDF]
|
|
|
|
 |
|
 T Monaghan, T Boswell, and Y R Mahida Recent advances in Clostridium difficile-associated disease Gut, June 1, 2008; 57(6): 850 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Halsey Current and future treatment modalities for Clostridium difficile-associated disease Am. J. Health Syst. Pharm., April 15, 2008; 65(8): 705 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Pelleschi Clostridium difficile-Associated Disease: Diagnosis, Prevention, Treatment, and Nursing Care Crit. Care Nurse, February 1, 2008; 28(1): 27 - 35. [Full Text] [PDF]
|
|
|
|
 |
|
 T Chandrasekar, N Naqvi, A Waddington, R. Cooke, H. Anijeet, C. Gradden, K. Abraham, and C. Wong Intravenous immunoglobulin therapy for refractory Clostridium difficile toxin colitis in chronic kidney disease: case reports and literature review NDT Plus, February 1, 2008; 1(1): 20 - 22. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Thompson Clostridium difficile-associated disease: update and focus on non-antibiotic strategies Age Ageing, January 1, 2008; 37(1): 14 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Emerson Clostridium difficile Associated Diarrhea, an Emerging Epidemic: Therapeutic Options Journal of Pharmacy Practice, August 1, 2007; 20(4): 347 - 353. [Abstract] [PDF]
|
|
|
|
 |
|
 D. M. Musher, N. Logan, V. Mehendiratta, N. A. Melgarejo, S. Garud, and R. J. Hamill Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide J. Antimicrob. Chemother., April 1, 2007; 59(4): 705 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Z Jodlowski, R. Oehler, L. W Kam, and I. Melnychuk Emerging Therapies in the Treatment of Clostridium difficile-Associated Disease Ann. Pharmacother., December 1, 2006; 40(12): 2164 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Surowiec, A. G Kuyumjian, M. A Wynd, and C. E Cicogna Past, Present, and Future Therapies for Clostridium difficile-Associated Disease Ann. Pharmacother., December 1, 2006; 40(12): 2155 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Bartlett Narrative Review: The New Epidemic of Clostridium difficile-Associated Enteric Disease. Ann Intern Med, November 21, 2006; 145(10): 758 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Babcock, T. J. Broering, H. J. Hernandez, R. B. Mandell, K. Donahue, N. Boatright, A. M. Stack, I. Lowy, R. Graziano, D. Molrine, et al. Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters Infect. Immun., November 1, 2006; 74(11): 6339 - 6347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Murphy, M. Vernon, and M. Cullen Intravenous immunoglobulin for resistant Clostridium difficile infection Age Ageing, January 1, 2006; 35(1): 85 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Starr Clostridium difficile associated diarrhoea: diagnosis and treatment BMJ, September 3, 2005; 331(7515): 498 - 501. [Full Text] [PDF]
|
|
|
|
 |
|
 L. V McFarland Alternative treatments for Clostridium difficile disease: what really works? J. Med. Microbiol., February 1, 2005; 54(2): 101 - 111. [Abstract] [Full Text] [PDF]
|
|